In addition to the studies performed combining immunotherapy with chemotherapy or radiotherapy, other studies have attempted to combine immune checkpoint inhibitors with other types of immunotherapeutic agents, such as IL-2 or IL-15, that act via a different mechanism of action, involving activation of immune anti-tumor effector functions. This evidence concerns the gene IL2 and neoplasm.